NL-OMON48406招募中2 期
Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736). - Donan trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •All patients must meet all of the following criteria:;1. Male or female subjects aged >50 years at time of study entry
- •2. Histopathological proven primary non-small cell lung cancer, with fully evaluable histological biopsies available
- •3. ECOG performance status of 0 or 1
- •4. AJCC stage I, II or IIIa as determined by contrast-enhanced CT chest-abdomen and F-18-FDG PET/CT: cT1cN0-1M0, cT2aN0-1M0 en cT3N0-1M0 (T3 separate nodule)
- •5. Solid appearance of the tumor on contrast-enhanced CT
- •6. Scheduled for resection with curative intent
- •7. Patients should be medically operable defined by:
- •8. Sufficient cardiopulmonary function
- •9. Major contra-indications for surgery.
- •10. No underlying immune disease (neutro- or lymphopenia, coagulation disorders) that could interfere with T-cell isolation
- •11. Life expectancy at least 6 months
- •12. Written informed consent and comply with study protocol for the duration of the study and follow-up
- •13. Adequate laboratory values (refer to study protocol)
排除标准
- •A patient will be excluded from participation in the trial if one or more of the following criteria are met:;1. Inability to lie supine for more than 30 minutes
- •2. Documented previous severe allergic reaction to iodine-based contrast media, despite adequate pre-medication.
- •3. Indication for cervical mediastinoscopy
- •4. Participation in another clinical study with an investigational product during the past 6 months
- •5. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- •6. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumour embolization, monoclonal antibodies) <6 months prior to the first dose of study drug
- •7. Any unresolved toxicity NCI CTCAE Grade >=2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •8. Patients with Grade >=2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
- •9. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab (MEDI4736) may be included only after consultation with the Study Physician.
- •10. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
- •11. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 6 months of the first dose of study drug
- •12. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.
- •13. History of allogenic organ transplantation.
- •14. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).
- •15. History of another primary malignancy except for: Malignancy treated with curative intent and with no known active disease >=5 years before the first dose of IP and of low potential risk for recurrence, Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, Adequately treated carcinoma in situ without evidence of disease
- •16. History of active primary immunodeficiency
- •17. Active infection including: tuberculosis, hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, human immunodeficiency virus (positive HIV 1/2 antibodies), Epstein Barr Virus (EBV, positive IgM antibodies), cytomegalo virus (CMV, positive IgM antibodies)
- •18. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (MEDI4736); exceptions apply.
- •19. Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab (MEDI4736). Note: Patients, if enrolled, should not receive live vaccine whilst receiving durvalumab (MEDI4736) and up to 30 days after the last dose of durvalumab (MEDI4736).
- •20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not wil
研究者
相似试验
进行中（未招募）
1 期
Imaging tumor-infiltrating T-cells in non-small cell lung cancer.EUCTR2019-000670-37-NLRadboud University Medical Center20
进行中（未招募）
1 期
Imaging of inflamed arteries in giant cell arteritis and inflamed joints in rheumatoid arthritis with a PET/CT scan.rheumatoid arthritis, giant cell arteritisCTIS2024-514489-38-01niversitair Medisch Centrum Groningen20
尚未招募
2 期
CD8 T cell imaging by positron emission tomography with 89Zr-Df-IAB22M2C in giant cell arteritis and rheumatoid arthritis: a pilot studyrheumatoid arthritisgiant cell arteritis (vasculitis)100038161001336110047066NL-OMON53860niversitair Medisch Centrum Groningen20
已完成
2 期
Imaging Tumor-infiltrating T-cells in Non-small Cell Lung CancerNon-small Cell Lung CancerNCT03853187Radboud University Medical Center20
招募中
不适用
A phase 2 immunoPET imaging study with ZED88082A/CED88004S in patients with Large B-cell lymphoma before and after CD19-directed CAR T-cell therapyNL-OMON21584MCG15